-
1 Comment
Harbin Gloria Pharmaceuticals Co., Ltd is currently in a long term downtrend where the price is trading 10.9% below its 200 day moving average.
From a valuation standpoint, the stock is 81.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Harbin Gloria Pharmaceuticals Co., Ltd's total revenue sank by 34.9% to $809M since the same quarter in the previous year.
Its net income has dropped by 114.5% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 106.3% to $-17M since the same quarter in the previous year.
Based on the above factors, Harbin Gloria Pharmaceuticals Co., Ltd gets an overall score of 1/5.
| ISIN | CNE100000QG8 |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Exchange | SHE |
| CurrencyCode | CNY |
| Beta | 0.4 |
|---|---|
| PE Ratio | 22.55 |
| Target Price | 3.23 |
| Market Cap | 6B |
| Dividend Yield | None |
Harbin Gloria Pharmaceuticals Co., Ltd engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is based in Harbin, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002437.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
